{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:46:28Z","timestamp":1793339188380,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-68511-7","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T13:27:55Z","timestamp":1722259675000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del\/CFTR variant genotype after elexacaftor\/tezacaftor\/ivacaftor treatment"],"prefix":"10.1038","volume":"14","author":[{"given":"Alice","family":"Castaldo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Iacotucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sveva","family":"Bagnasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Fevola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Carnovale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Cernera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Gelzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Terlizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"68511_CR1","doi-asserted-by":"publisher","first-page":"10358","DOI":"10.3390\/ijms241210358","volume":"24","author":"K Kleinfelder","year":"2023","unstructured":"Kleinfelder, K. et al. Theratyping of the rare CFTR genotype A559T in rectal organoids and nasal cells reveals a relevant response to Elexacaftor (VX-445) and Tezacaftor (VX-661) combination. Int. J. Mol. Sci. 24, 10358 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"68511_CR2","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/humu.23741","volume":"40","author":"F Amato","year":"2019","unstructured":"Amato, F. et al. Two CFTR mutations within codon 970 differently impact on the chloride channel functionality. Hum. Mutat. 40, 742\u2013748 (2019).","journal-title":"Hum. Mutat."},{"key":"68511_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.14639\/0392-100X-1328","volume":"37","author":"AM Di Lullo","year":"2017","unstructured":"Di Lullo, A. M. et al. An \u201cex vivo model\u201d contributing to the diagnosis and evaluation of new drugs in cystic fibrosis. Acta Otorhinolaryngol. Ital. 37, 207\u2013213 (2017).","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"68511_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1656","volume":"9","author":"V Terlizzi","year":"2021","unstructured":"Terlizzi, V. et al. Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype. Mol. Genet. Genomic Med. 9, e1656 (2021).","journal-title":"Mol. Genet. Genomic Med."},{"key":"68511_CR5","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3390\/antibiotics10070828","volume":"10","author":"M Comegna","year":"2021","unstructured":"Comegna, M. et al. Elexacaftor\u2013tezacaftor\u2013ivacaftor therapy for Cystic Fibrosis patients with the F508del\/unknown genotype. Antibiotics (Basel) 10, 828 (2021).","journal-title":"Antibiotics (Basel)"},{"key":"68511_CR6","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3390\/genes12081178","volume":"12","author":"V Terlizzi","year":"2021","unstructured":"Terlizzi, V. et al. Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor therapy in three subjects with the Cystic Fibrosis genotype Phe508del\/unknown and advanced lung disease. Genes (Basel) 12, 1178 (2021).","journal-title":"Genes (Basel)"},{"key":"68511_CR7","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","volume":"21","author":"J Guo","year":"2022","unstructured":"Guo, J., Garratt, A. & Hill, A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. J. Cyst. Fibros. 21, 456\u2013462 (2022).","journal-title":"J. Cyst. Fibros."},{"key":"68511_CR8","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3390\/ph16030410","volume":"16","author":"M Bacalhau","year":"2023","unstructured":"Bacalhau, M. et al. Elexacaftor\u2013tezacaftor\u2013ivacaftor: A life-changing triple combination of CFTR modulator drugs for Cystic Fibrosis. Pharmaceuticals (Basel) 16, 410 (2023).","journal-title":"Pharmaceuticals (Basel)"},{"key":"68511_CR9","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman, H. G. M. et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial. Lancet 394, 1940\u20131948 (2019).","journal-title":"Lancet"},{"key":"68511_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","volume":"203","author":"M Griese","year":"2021","unstructured":"Griese, M. et al. Safety and efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24 weeks or longer in people with Cystic Fibrosis and one or more F508del alleles: Interim results of an open-label phase 3 clinical trial. Am. J. Respir. Crit. Care Med. 203, 381\u2013385 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"68511_CR11","first-page":"554","volume":"10","author":"N Kapouni","year":"2023","unstructured":"Kapouni, N., Moustaki, M., Douros, K. & Loukou, I. Efficacy and safety of Elexacaftor\u2013Tezacaftor\u2013Ivacaftor in the treatment of Cystic Fibrosis: A systematic review. Children (Basel) 10, 554 (2023).","journal-title":"Children (Basel)"},{"key":"68511_CR12","volume":"13","author":"A Zaher","year":"2021","unstructured":"Zaher, A., ElSaygh, J., Elsori, D., ElSaygh, H. & Sanni, A. A review of trikafta: Triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy. Cureus 13, e16144 (2021).","journal-title":"Cureus"},{"key":"68511_CR13","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.3390\/jcm11154277","volume":"11","author":"L Macconi","year":"2022","unstructured":"Macconi, L. et al. Early effects of Elexacaftor\u2013Tezacaftor\u2013Ivacaftor therapy on magnetic resonance imaging in patients with Cystic Fibrosis and advanced lung disease. J. Clin. Med. 11, 4277 (2022).","journal-title":"J. Clin. Med."},{"key":"68511_CR14","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3390\/jcm11041021","volume":"11","author":"V Carnovale","year":"2022","unstructured":"Carnovale, V. et al. Elexacaftor\/Tezacaftor\/Ivacaftor in patients with Cystic Fibrosis homozygous for the F508del mutation and advanced lung disease: A 48-week observational study. J. Clin. Med. 11, 1021 (2022).","journal-title":"J. Clin. Med."},{"key":"68511_CR15","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton, P. G. et al. Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a single Phe508del allele. N. Engl. J. Med. 381, 1809\u20131819 (2019).","journal-title":"N. Engl. J. Med."},{"key":"68511_CR16","doi-asserted-by":"publisher","first-page":"6900","DOI":"10.3390\/jcm11236900","volume":"11","author":"V Carnovale","year":"2022","unstructured":"Carnovale, V. et al. Cystic Fibrosis patients with F508del\/minimal function genotype: Laboratory and nutritional evaluations after one year of Elexacaftor\/Tezacaftor\/Ivacaftor treatment. J. Clin. Med. 11, 6900 (2022).","journal-title":"J. Clin. Med."},{"key":"68511_CR17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jcf.2023.01.007","volume":"22","author":"DH Tewkesbury","year":"2023","unstructured":"Tewkesbury, D. H., Athwal, V., Bright-Thomas, R. J., Jones, A. M. & Barry, P. J. Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on liver tests at a large single adult cystic fibrosis centre. J. Cyst. Fibros. 22, 256\u2013262 (2023).","journal-title":"J. Cyst. Fibros."},{"key":"68511_CR18","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.japh.2023.02.015","volume":"63","author":"M Wood","year":"2023","unstructured":"Wood, M. et al. Incidence of transaminitis in adults with cystic fibrosis taking elexacaftor\/tezacaftor\/ivacaftor. J. Am. Pharm. Assoc. 63, 920\u2013924 (2023).","journal-title":"J. Am. Pharm. Assoc."},{"key":"68511_CR19","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jcf.2023.06.013","volume":"22","author":"V Terlizzi","year":"2023","unstructured":"Terlizzi, V. et al. Hyperbilirubinemia and Gilbert\u2019s syndrome in Cystic Fibrosis patients treated with elexacaftor\/tezacaftor\/ivacaftor. J. Cyst. Fibros. 22, 1130\u20131132 (2023).","journal-title":"J. Cyst. Fibros."},{"key":"68511_CR20","volume":"34","author":"M Salehi","year":"2021","unstructured":"Salehi, M., Iqbal, M., Dube, A., AlJoudeh, A. & Edenborough, F. Delayed hepatic necrosis in a cystic fibrosis patient taking Elexacaftor\/Tezacaftor\/Ivacaftor (Kaftrio). Respir. Med. Case Rep. 34, 101553 (2021).","journal-title":"Respir. Med. Case Rep."},{"key":"68511_CR21","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jcf.2021.05.017","volume":"20","author":"D Stylemans","year":"2021","unstructured":"Stylemans, D., Fran\u00e7ois, S., Vincken, S., Verbanck, S. & Vanderhelst, E. A case of self-limited drug induced liver injury under treatment with elexacaftor\/tezacaftor\/ivacaftor: When it is worth taking the risk. J. Cyst. Fibros. 20, 712\u2013714 (2021).","journal-title":"J. Cyst. Fibros."},{"key":"68511_CR22","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1016\/j.jcf.2021.07.001","volume":"21","author":"S Lowry","year":"2022","unstructured":"Lowry, S., Mogayzel, P. J., Oshima, K. & Karnsakul, W. Drug-induced liver injury from elexacaftor\/ivacaftor\/tezacaftor. J. Cyst. Fibros. 21, e99\u2013e101 (2022).","journal-title":"J. Cyst. Fibros."},{"key":"68511_CR23","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","volume":"22","author":"JK Bower","year":"2023","unstructured":"Bower, J. K. et al. Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study. J. Cyst. Fibros. 22, 730\u2013737 (2023).","journal-title":"J. Cyst. Fibros."},{"key":"68511_CR24","doi-asserted-by":"publisher","first-page":"1327958","DOI":"10.3389\/fmolb.2023.1327958","volume":"10","author":"A Castaldo","year":"2024","unstructured":"Castaldo, A. et al. One year of treatment with elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes. Front. Mol. Biosci. 10, 1327958 (2024).","journal-title":"Front. Mol. Biosci."},{"key":"68511_CR25","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1515\/cclm-2015-1151","volume":"54","author":"M Gelzo","year":"2016","unstructured":"Gelzo, M. et al. Reduced absorption and enhanced synthesis of cholesterol in patients with cystic fibrosis: A preliminary study of plasma sterols. Clin. Chem. Lab. Med. 54, 1461\u20131466 (2016).","journal-title":"Clin. Chem. Lab. Med."},{"key":"68511_CR26","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1515\/cclm-2019-1112","volume":"58","author":"M Gelzo","year":"2020","unstructured":"Gelzo, M. et al. Influence of pancreatic status on circulating plasma sterols in patients with cystic fibrosis. Clin. Chem. Lab. Med. 58, 1725\u20131730 (2020).","journal-title":"Clin. Chem. Lab. Med."},{"key":"68511_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245302","volume":"16","author":"F Amato","year":"2021","unstructured":"Amato, F. et al. Impaired cholesterol metabolism in the mouse model of cystic fibrosis. A preliminary study. PLoS One 16, e0245302 (2021).","journal-title":"PLoS One"},{"key":"68511_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1242\/jcs.03350","volume":"120","author":"M Gentzsch","year":"2007","unstructured":"Gentzsch, M., Choudhury, A., Chang, X. B., Pagano, R. E. & Riordan, J. R. Misassembled mutant DeltaF508 CFTR in the distal secretory pathway alters cellular lipid trafficking. J. Cell Sci. 120, 447\u2013455 (2007).","journal-title":"J. Cell Sci."},{"key":"68511_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000646","author":"ZM Sellers","year":"2023","unstructured":"Sellers, Z. M. et al. Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations. Hepatology. https:\/\/doi.org\/10.1097\/HEP.0000000000000646 (2023).","journal-title":"Hepatology."},{"key":"68511_CR30","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1515\/cclm-2017-0553","volume":"56","author":"A Bergougnoux","year":"2018","unstructured":"Bergougnoux, A. et al. Multicenter validation study for the certification of a CFTR gene scanning method using next generation sequencing technology. Clin. Chem. Lab. Med. 56, 1046\u20131053 (2018).","journal-title":"Clin. Chem. Lab. Med."},{"key":"68511_CR31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jcf.2007.12.004","volume":"7","author":"R Tomaiuolo","year":"2008","unstructured":"Tomaiuolo, R. et al. Epidemiology and a novel procedure for large scale analysis of CFTR rearrangements in classic and atypical CF patients: A multicentric Italian study. J. Cyst. Fibros. 7, 347\u2013351 (2008).","journal-title":"J. Cyst. Fibros."},{"key":"68511_CR32","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12890-018-0766-6","volume":"18","author":"V Terlizzi","year":"2018","unstructured":"Terlizzi, V. et al. Clinical expression of cystic fibrosis in a large cohort of Italian siblings. BMC Pulm. Med. 18, 196 (2018).","journal-title":"BMC Pulm. Med."},{"key":"68511_CR33","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1001\/jama.2009.1295","volume":"302","author":"JR Bartlett","year":"2009","unstructured":"Bartlett, J. R. et al. Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 302, 1076\u20131083 (2009).","journal-title":"JAMA"},{"key":"68511_CR34","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1111\/crj.12796","volume":"12","author":"A Elce","year":"2018","unstructured":"Elce, A. et al. Supervised physical exercise improves clinical, anthropometric and biochemical parameters in adult cystic fibrosis patients: A 2-year evaluation. Clin. Respir. J. 12, 2228\u20132234 (2018).","journal-title":"Clin. Respir. J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68511-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68511-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68511-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T13:32:11Z","timestamp":1722259931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68511-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["68511"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-68511-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]},"assertion":[{"value":"17 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17422"}}